You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Dovato (dolutegravir/lamivudine) is now available in Ireland for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3

Vocabria (cabotegravir) injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. 4

For further information on any of these products see the links to the Summary of Product Characteristics available at the top of this page.


  1. Cahn P et al. J Acquir Immunde Defic Syndr. 2020;83(3):310-318
  2. van Wyk J;IAS;2019;1-16
  3. Dovato Summary of Characteristics. Available at Last accessed: July 2023
  4. Vocabria Summary of Characteristics. Available at Last accessed: July 2023.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor.